The Study of Envafolimab Combined With Concurrent Chemoradiotherapy In LS-SCLC
Condition: Lung Neoplasms Interventions: Drug: Envafolimab combined with concurrent chemoradiotherapy (Hypofractionated radiotherapy); Drug: Envafolimab combined with concurrent chemoradiotherapy (Conventional Radiotherapy) Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Academies | Cancer | Cancer & Oncology | China Health | Hospitals | Research | Small Cell Lung Cancer | Study